Angiogenesis of breast cancer.
Schneider
Bryan P
BP
Division of Hematology-Oncology, Indiana University, 535 Barnhill Dr, RT-473 Indianapolis, IN 46202, USA. bpschnei@iupui.edu
Miller
Kathy D
KD
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000098:blood supply* / Q000473:pathology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor